Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
Given the results from the BILCAP trial presented at ASCO, would you change to or initiate therapy with capecitabine for patients with biliary tract cancer in the post-operative setting?
For patients receiving adjuvant gemcitabine alone, would you now switch to adjuvant capecitabine alone?
Answer from: Medical Oncologist at Academic Institution
The BILCAP study represents the first data from a large, randomized, prospective, adequately-powered trial demonstrating a survival benefit for adjuvant therapy in this difficult-to-treat and relatively rare cancer.Given that capecitabine is relatively well tolerated, I would likely change from gemc...
Sign in or Register to read more